"Global Lung Cancer Diagnostic and Screening Market Overview:
Global Lung Cancer Diagnostic and Screening Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Lung Cancer Diagnostic and Screening Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Lung Cancer Diagnostic and Screening involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Lung Cancer Diagnostic and Screening Market:
The Lung Cancer Diagnostic and Screening Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Lung Cancer Diagnostic and Screening Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Lung Cancer Diagnostic and Screening Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Lung Cancer Diagnostic and Screening market has been segmented into:
Biomarkers Test (EGFR Mutation Test
KRAS Mutation Test
ALK Test
HER2 Test
Others
By Application, Lung Cancer Diagnostic and Screening market has been segmented into:
Computed Tomography (CT
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Lung Cancer Diagnostic and Screening market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Lung Cancer Diagnostic and Screening market.
Top Key Players Covered in Lung Cancer Diagnostic and Screening market are:
Abbott
Amgen Inc.
Illuminainc.
Thermo Fisher Scientific Inc.
Lepu Medical Technology(Beijing)Co.
Ltd.
AstraZeneca
F. Hoffmann-La Roche Ltd
Laboratory Corporation of America Holdings.
Agilent Technologiesinc.
QIAGEN
Quest Diagnostics Incorporated.
NeoGenomics Laboratories.
Myriad Geneticsinc.
GRAIL
LLC.
DELFI Diagnostics.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Lung Cancer Diagnostic and Screening Market by Type
4.1 Lung Cancer Diagnostic and Screening Market Snapshot and Growth Engine
4.2 Lung Cancer Diagnostic and Screening Market Overview
4.3 Biomarkers Test (EGFR Mutation Test
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Biomarkers Test (EGFR Mutation Test: Geographic Segmentation Analysis
4.4 KRAS Mutation Test
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 KRAS Mutation Test: Geographic Segmentation Analysis
4.5 ALK Test
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 ALK Test: Geographic Segmentation Analysis
4.6 HER2 Test
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 HER2 Test: Geographic Segmentation Analysis
4.7 Others
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Others: Geographic Segmentation Analysis
Chapter 5: Lung Cancer Diagnostic and Screening Market by Application
5.1 Lung Cancer Diagnostic and Screening Market Snapshot and Growth Engine
5.2 Lung Cancer Diagnostic and Screening Market Overview
5.3 Computed Tomography (CT
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Computed Tomography (CT: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Lung Cancer Diagnostic and Screening Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ABBOTT
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 AMGEN INC.
6.4 ILLUMINAINC.
6.5 THERMO FISHER SCIENTIFIC INC.
6.6 LEPU MEDICAL TECHNOLOGY(BEIJING)CO.
6.7 LTD.
6.8 ASTRAZENECA
6.9 F. HOFFMANN-LA ROCHE LTD
6.10 LABORATORY CORPORATION OF AMERICA HOLDINGS.
6.11 AGILENT TECHNOLOGIESINC.
6.12 QIAGEN
6.13 QUEST DIAGNOSTICS INCORPORATED.
6.14 NEOGENOMICS LABORATORIES.
6.15 MYRIAD GENETICSINC.
6.16 GRAIL
6.17 LLC.
6.18 DELFI DIAGNOSTICS.
Chapter 7: Global Lung Cancer Diagnostic and Screening Market By Region
7.1 Overview
7.2. North America Lung Cancer Diagnostic and Screening Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Biomarkers Test (EGFR Mutation Test
7.2.4.2 KRAS Mutation Test
7.2.4.3 ALK Test
7.2.4.4 HER2 Test
7.2.4.5 Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Computed Tomography (CT
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Lung Cancer Diagnostic and Screening Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Biomarkers Test (EGFR Mutation Test
7.3.4.2 KRAS Mutation Test
7.3.4.3 ALK Test
7.3.4.4 HER2 Test
7.3.4.5 Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Computed Tomography (CT
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Lung Cancer Diagnostic and Screening Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Biomarkers Test (EGFR Mutation Test
7.4.4.2 KRAS Mutation Test
7.4.4.3 ALK Test
7.4.4.4 HER2 Test
7.4.4.5 Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Computed Tomography (CT
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Lung Cancer Diagnostic and Screening Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Biomarkers Test (EGFR Mutation Test
7.5.4.2 KRAS Mutation Test
7.5.4.3 ALK Test
7.5.4.4 HER2 Test
7.5.4.5 Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Computed Tomography (CT
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Lung Cancer Diagnostic and Screening Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Biomarkers Test (EGFR Mutation Test
7.6.4.2 KRAS Mutation Test
7.6.4.3 ALK Test
7.6.4.4 HER2 Test
7.6.4.5 Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Computed Tomography (CT
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Lung Cancer Diagnostic and Screening Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Biomarkers Test (EGFR Mutation Test
7.7.4.2 KRAS Mutation Test
7.7.4.3 ALK Test
7.7.4.4 HER2 Test
7.7.4.5 Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Computed Tomography (CT
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Lung Cancer Diagnostic and Screening Scope:
|
Report Data
|
Lung Cancer Diagnostic and Screening Market
|
|
Lung Cancer Diagnostic and Screening Market Size in 2025
|
USD XX million
|
|
Lung Cancer Diagnostic and Screening CAGR 2025 - 2032
|
XX%
|
|
Lung Cancer Diagnostic and Screening Base Year
|
2024
|
|
Lung Cancer Diagnostic and Screening Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Abbott, Amgen Inc., Illuminainc., Thermo Fisher Scientific Inc., Lepu Medical Technology(Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologiesinc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Geneticsinc., GRAIL, LLC., DELFI Diagnostics..
|
|
Key Segments
|
By Type
Biomarkers Test (EGFR Mutation Test
KRAS Mutation Test
ALK Test
HER2 Test
Others
By Applications
Computed Tomography (CT
|
